Cabotegravir Dissolvable Pellet Implants and Cabotegravir Injectable Depot

Gustavo Doncel, MD, PhD Executive and Scientific Director CONRAD Eastern Virginia Medical School Norfolk, VA USA












What is cabotegravir (CAB)?

(Cabotegravir)

- CAB is a long acting, potent, anti-retroviral drug from the class of integrase inhibitors
- It stops the HIV virus from integrating into the DNA of the healthy human cells, preventing HIV from replicating and spreading elsewhere in the body
- CAB as a long-acting injectable (called APRETUDE) is approved by the FDA and recommended by WHO as an additional HIV prevention option



CAB Pellets and CAB Depot in brief

Administered under the skin by healthcare provider similarly to contraceptives


Longer duration (~6-12 months); SC



Users of all ages and genders

Approved CAB product highly effective at preventing HIV; must be injected IM every 2 months








CAB Depot

CAB Pellets

CAB Pellets




- Small, cylindrical shape, containing mostly CAB
- One dose equals multiple pellets
 - Target dosing up to 8-10 pellets implanted with a single insertion
- Slowly dissolve, so there's nothing to remove
 - In the case of severe adverse reaction, pellets could be removed 1-3 months after implanted
- Ingredients (other than CAB) are generally regarded as safe
- Low cost and simple to manufacture
- Potential to be developed in combination with other antivirals or contraceptives









How are CAB Pellets inserted?



CAB Depot


- What do we mean by "depot"?
 - Depot is a small bubble-like gel injected under the skin with CAB contained or stored inside
 - As the bubble dissolves, CAB is slowly released
- The rate of release is controlled by the natural ingredients that make up the bubble (depot)





How is CAB Depot injected?

- Provider uses a small, thin needle to deliver the depot under the skin
 - Minimal pain
 - Quick injection
 - ✓ Long-lasting



- Depot slowly dissolves and releases CAB at steady rate
 - ✓ Confers protection for ~ 6 months
 - ✓ Two injections per year
 - Nothing to remove







Advantages of CAB Pellet and CAB Depot versus CAB-LA




Studies Conducted to Date and Key Take-Aways



- Several formulation improvements developed
- Increased drug amount & release rate

Qualitative




- Discrete Choice Experiments
- End-user preferences (SA, Kenya, eSwatini)

Strong preference among African women for long acting and implantable products



Preclinical Animal Testing

- Rat Drug Release Rate Studies
- Monkey Drug Release Rate Studies
 - Long term monkey study (Depot)





- Initial FDA engagements ongoing
- Formal Pre-Investigational New Drug (IND) Meetings pending for clinical testing


Promising data showing safety and target release rate in rats and monkeys



Key questions to address - next steps

- Can we achieve the **desired duration** of 12 month for the pellets and 6 months for the injectable depot?
- Until when can the products be safely removed if needed?
- How long does CAB persist in the body after the period of protection ends? In other words, what is the "tail"?
- Are the depot and pellet safe and well tolerated in women?
- Do they achieve levels associated with protection?

Next steps and development timeline



Acknowledgements



This program was made possible by the generous support of the American people through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the U.S. Agency for International Development (USAID).

The contents in this presentation are those of the presenter and do not necessarily reflect the view of the U.S. President's Emergency Plan for AIDS Relief, the U.S. Agency for International Development or the U.S. Government.









































Acknowledgements


























Eastern Virginia Medical School



